Skip to main content

Advertisement

Table 2 “Screen positive” copy number variations (CNVs) in 13 cancer cases and two controls mapped to reported gains and losses in the Integrated Genomic Analysis of Ovarian Cancer (IGAOC) study [11]

From: Abnormal plasma DNA profiles in early ovarian cancer using a non-invasive prenatal testing platform: implications for cancer screening

Subject number Age (years) Study group FIGO Stage Percept™ call for aneuploidy Detected CNVs ≥ 15 Mb mapped according to IGAOCa
  Highly specific Moderately specific Non-specific
1 76 Early stage cancer 2C No call Chr 3q gain Chr 12p gain Chr 20q terminal gain Chr 5q segmental loss Chr 8p loss Chr 9p loss   Chr 5p gain Chr 7q segmental loss
2 65 Early stage cancer 2C No call Chr 3q terminal gain Chr 20 gain Chr 4q loss Chr 7p loss Chr 13q segmental loss Chr 15q segmental loss Chr 6p gain Chr 2q interstitial gain Chr 18q segmental gain
3 48 Early stage cancer 1C Low risk Chr 12p terminal gain   
4 71 Early stage cancer 2C Low risk Chr 3q interstitial gain Chr 8q gain   
5 38 Early stage cancer 1C Low risk Chr 8q terminal gain   Chr 3p terminal gain
6 47 Early stage cancer 2A Low risk Chr 8q terminal gain   
7 54 Advanced stage cancer 4 No call Chr 3q terminal gain Chr 8 gain Chr 5q loss Chr 13 loss Chr 15 loss Chr 17 loss Chr 18 loss Chr 22 loss Chr 14 loss Chr 5p gain Chr 9p gain
8 57 Advanced stage cancer 3B Low risk Chr 8q terminal gain Chr 8p terminal loss Chr 1q interstitial gain Chr 6p gain Chr 1p interstitial gain Chr 11q segmental gain
9 60 Advanced stage cancer 3A1 Low risk Chr 20 gain   
10 83 Advanced stage cancer 3A Low risk    Chr 11q interstitial gain
11 33 Advanced stage cancer 3C No call Chr 8q terminal gain Chr 12p terminal gain Chr 4q segmental loss Chr 5q interstitial loss Chr 6q terminal loss Chr 8p loss Chr 9p terminal loss Chr 13 segmental loss Chr 15 segmental loss Chr 17q segmental loss Chr 22 loss Chr 6p segmental gains Chr 7q segmental gains Chr 1p segmental gains Chr 2 segmental gains Chr 5p gain Chr 11q interstitial gain Chr 18q segmental gain Chr 1p segmental loss Chr 10p loss Chr 11q terminal loss Chr 21 loss
12 58 Advanced stage cancer 3C No call Chr 3q gain Chr 4p loss Chr 9q loss Chr 13 loss Chr 1q gain Chr 6p gain Chr 7q terminal gain Chr 11p loss Chr 5p loss Chr 7p terminal loss Chr 10p gain Chr 18 gain
13 66 Advanced stage cancer 3C Monosomy 18 Chr 20q gain Chr 8q terminal segmental gain   
14 44 Benign control NA Low risk Chr 20q segmental gain   
15 53 Benign control NA Low risk Chr 20q gain   
  1. aCNVs are categorized according to IGAOC analysis [8]. The IGAOC found 8 significantly gained chromosome arms (5 present in > 50 % of tumor samples), and 22 significantly deleted chromosome arms (18 present in > 50 %). We used the following definitions: highly specific CNV, statistically significant gain or loss (q value < 0.25) with frequency in > 50 %; Moderately specific CNV, statistically significant gain or loss (q value < 0.25) with frequency in < 50 %; non-specific CNV, gain or loss with q value > 0.25